FEATURED EDITORIAL
Praise to the RNA innovators, and our innovative service providers. You’ve brought us a long way. Still, that progress hasn’t necessarily made it easier to strategize the outsourcing of specific RNA-based projects. We’ve expanded development programs therapeutically and dialed up nuanced production requirements. So the current question is what will the RNA outsourcing ecosystem look like a few years from now? Here’s some expert analysis.
- DEA Reveals Hidden Costs Of Analytical Validation Guidelines
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
- Your CDMO Can Make It, But Can Your Market Afford It?
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- CDMO Selection Beyond Capabilities And Price
- August 2026 — CDMO Opportunities And Threats Report
- Dr. Heidi Overton And The FDA: An Outsourcing Perspective
GUEST COLUMNISTS
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
CDMO Selection Beyond Capabilities And Price
Some of the most useful information relevant to CDMO selection is also the hardest to obtain. Here are suggestions for uncovering data that tells the whole capability story.
-
August 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Building Sustainable Biopharma Supply Chains Starts With Procurement
Nearly all the industry's emissions happen upstream from core manufacturing functions. This puts sustainability almost entirely on the shoulders of purchasing.
-
Why You Should Measure Comparability Debt Before Ever Starting A Study
When analytical capability and process understanding fail to keep pace with a drug candidate, the technical uncertainty creates debt that's difficult to pay down.
-
What FDA Inspectors Want From Your OOS File
Read enough FDA warning letters and a pattern emerges: Investigators rarely cite a retest that was performed badly. They cite a retest that nobody justified in writing. Let's take a closer look.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
PHARMA OUTSOURCING WHITE PAPERS
-
Mammalian Cell Line Development
Explores how modern cell line engineering boosts speed, stability, and scalability across biologics, with practical insights to cut risk and improve readiness for downstream development.
-
Coordinated Development As An Execution Framework
See how integrating clinical, development, manufacturing, and supply functions within a single execution framework can transform program performance and accelerate development success.
-
Rational Design And Material-sparing Strategies For Enabled Intermediates And Drug Products
A material-sparing strategy integrating formulation mapping, lab-scale spray drying, and compact screening can accelerate risk identification and inform first-round tablet formulation decisions for poorly soluble APIs.
-
Super Short Activated CAR-T Process
Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.
-
A CFO's Guide To Driving Growth
Navigate the evolving biotech landscape and secure venture capital with insights on strategic partnerships and investor expectations.
-
The Benefits Of End-To-End Formulation And Fill/Finish Of Biologics
Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
REPORTING
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Design Verification Done Right: Smarter Strategies For Prefillable Syringes
- IND In As Little As 6 Months: Now Beyond mAbs - Accelerating Bispecifics, Fc-Fusions And High-Concentration Biologics To The Clinic
- Scaling Cell And Gene Therapy Manufacturing
- Mastering The Path: Developing Processes For Successful Clinical-Grade mRNA Manufacturing
- De-Risking The Path To GMP Manufacturing At Another Organization